Syneos Health announced the launch of a Decentralized Clinical Trial Site Network to drive appropriate DCT adoption and enable high quality delivery of DCTs and digital health technology solutions. The introduction of the Syneos Health DCT Site Network complements the Company’s existing Site Advocacy Group, continuing the momentum for decentralized solutions to bring clinical trials closer to the patient. The novel DCT Site Network was created by leveraging Syneos Health’s global connections of Catalyst Sites, Networks and experienced Principal Investigators. First launching in the US and Canada, the DCT Site Network will cover various therapeutic areas such as Internal and General Medicine, Family Practice, Neurology, Endocrinology, Pediatrics, Psychiatry, Dermatology, Cardiology, Obstetrics and Gynecology, Ophthalmology, and Respiratory. Over time, Syneos Health will expand the network to include numerous sites across Europe and APAC.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SYNH:
- Syneos Health Unveils New Decentralized Clinical Trial Site Network to Drive DCT Adoption
- Baird sees more value in Syneos than market, but says buyer would ‘need resolve’
- Syneos Health jumps following report on new effort to sell itself
- Syneos Health hires Bank of America to help seek buyer, Reuters says
- Syneos Health price target raised to $51 from $42 at Baird